Evidence map›Paper›PMID 40908356›Full record

Trial reportNature medicine2025

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.

Elisabeth M Jongbloed, Noor Wortelboer, Vanja de Weerd, Corine M Beaufort, Kirsten Ruigrok-Ritstier, Mai N Van, Jaco Kraan, Annette A van Zweeden, Annemieke van der Padt-Pruijsten, Lisanne C Hamming and 6 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elisabeth M Jongbloed *Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Noor Wortelboer *Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID http://orcid.org/0009-0006-1649-748X
Vanja de WeerdDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Corine M BeaufortDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Kirsten Ruigrok-RitstierDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Mai N VanDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Jaco KraanDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0001-7445-7984
Annette A van ZweedenDepartment of Medical Oncology, Amstelland Hospital, Amstelveen, the Netherlands.
Annemieke van der Padt-PruijstenDepartment of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands.
Lisanne C HammingDepartment of Medical Oncology, Frisius MC Leeuwarden, Leeuwarden, the Netherlands.
Inge R KoningsDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Gabe S SonkeDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-8088-9628
Esther Oomen-de HoopDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0003-2506-3852
John W M MartensDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0002-3428-3366
Agnes JagerDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0002-7713-1450
Saskia M WiltingDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. s.wilting@erasmusmc.nl.ORCID http://orcid.org/0000-0002-2838-841X

Funding

Breast Cancer Now (BCN) 2018NovPCC100
6 · The paper itself

Abstract

CDK4/6 inhibitors (CDK4/6i) improve outcome in patients with advanced estrogen receptor-positive, HER2

Indexed as

Breast NeoplasmsCirculating Tumor DNACyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAdultAgedFemaleHumansMiddle AgedProgression-Free SurvivalQuality of LifeCDK4 protein, humanCDK6 protein, humanCirculating Tumor DNACyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase Inhibitors

Identifiers

PMID40908356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.